Cholesterol Management in Toledo, Ohio: The First Oral PCSK9 Inhibitor Is Here
- Jul 19
- 4 min read
For patients in Toledo, Maumee, Perrysburg, Sylvania, and across Northwest Ohio who struggle to reach their LDL cholesterol (low-density lipoprotein, the so-called "bad" cholesterol) goals despite statins, diet, and exercise, a meaningful new option has arrived. The FDA has approved enlicitide (Lipfendra), the first oral PCSK9 inhibitor (a medication that blocks a protein in the liver called PCSK9, allowing the body to remove more LDL from the bloodstream). At Toledo Cardiology Consultants, we want our patients to understand what this approval means, who may benefit, and how it fits into a comprehensive cholesterol management plan.
WHY PCSK9 INHIBITORS MATTER
PCSK9 inhibitors have for years represented one of the most powerful classes of LDL-lowering therapy available. By blocking the PCSK9 protein, these medications prevent the liver from destroying the receptors it uses to pull LDL out of the bloodstream. The result is a substantial, sustained reduction in circulating LDL. Lowering LDL is one of the most effective strategies known to reduce the risk of heart attack, stroke, and cardiovascular death.
The limitation, until now, has been delivery. All previously approved PCSK9 inhibitors required subcutaneous injections (shots administered under the skin), typically every two to four weeks. For some patients, that barrier, whether related to needle aversion, cost, or access, made a highly effective therapy difficult to sustain.
WHAT ENLICITIDE (LIPFENDRA) IS
Enlicitide, sold under the brand name Lipfendra, is the first FDA-approved oral PCSK9 inhibitor. It is taken once daily as a pill and is indicated for adults who need additional LDL lowering beyond what diet, exercise, and existing cholesterol-lowering therapies, including statins (medications that reduce the liver's production of cholesterol), have already achieved. Clinical studies have demonstrated that enlicitide significantly lowers LDL cholesterol, adding meaningful reduction on top of background therapy. Long-term studies evaluating its impact on rates of heart attack and stroke are ongoing, and Toledo Cardiology will continue to follow that data closely.
It is important to understand that enlicitide is not a replacement for foundational therapy. Evidence consistently supports that effective LDL reduction requires a layered approach. Research presented in the 2019 REALITY study found that only 3% of high-risk patients reached an LDL target below 55 mg/dL, and fewer than 15% reached below 70 mg/dL. That gap reflects the need for intensified, stepwise lipid-lowering therapy (treatment designed to progressively reduce LDL through multiple medication classes). Enlicitide now gives physicians and patients one more well-tolerated step in that progression. You can read more about why aggressive LDL management matters in our post on cholesterol management in Toledo, Ohio and why lowering LDL sooner saves lives after a heart attack.
WHO MAY BENEFIT
Enlicitide may be especially relevant for patients who have one or more of the following:
Familial hypercholesterolemia (an inherited condition that causes significantly elevated LDL from birth, often resistant to diet and standard medications alone)
Established cardiovascular disease, including prior heart attack or coronary artery disease (narrowing or blockage of the arteries that supply the heart)
Persistently high LDL despite maximally tolerated statin therapy
Statin intolerance (an inability to tolerate statins, most commonly due to muscle-related symptoms), though it is worth noting that the true prevalence of confirmed statin intolerance is under 7% based on established clinical definitions
If you have been told your cholesterol is not at goal, or if you have struggled with injectable PCSK9 inhibitors in the past, this approval is worth discussing with your cardiologist. Managing cardiovascular risk also involves blood pressure control, which you can learn about in our overview of hypertension in Toledo, Ohio, as well as lifestyle factors covered in our guide to a heart-healthy diet in Toledo, Ohio.
WHAT THIS MEANS FOR PREVENTIVE CARDIOLOGY IN NORTHWEST OHIO
The approval of the first oral PCSK9 inhibitor represents a genuine advance in preventive cardiology (the subspecialty focused on identifying and reducing cardiovascular risk before a heart attack or stroke occurs). It expands the toolkit available to cardiologists managing high-risk lipid profiles and removes one of the practical barriers that has kept a potent therapy out of reach for some patients. At Toledo Cardiology Consultants, we are actively evaluating which of our patients may be appropriate candidates and will be incorporating this option into individualized treatment plans as clinical evidence continues to develop.
Related Reading from Toledo Cardiology
Schedule Your Appointment in Toledo
If you are a patient in Toledo, Perrysburg, Bowling Green, Findlay, or the surrounding Northwest Ohio and southeast Michigan region and have questions about your cholesterol, your current medications, or whether enlicitide may be appropriate for you, our team is ready to help. Please contact our office to schedule an appointment. New patient paperwork is available on our website, and our office is conveniently located with parking on site.
